Evidence map›Paper›PMID 25765001›Full record

ArticleScientific reports2015

Association of FPGS genetic polymorphisms with primary retroperitoneal liposarcoma.

Chengli Miao, Ding Liu, Feng Zhang, Youxin Wang, Yanbin Zhang, Junhui Yu, Zhanzhi Zhang, Gang Liu, Bing Li, Xing Liu and 1 more

Open access · goldAbstract read
In one paragraph

Article in Scientific reports, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
1.2field-weighted citation impact, top 19% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 10 citations in OpenAlex.

  1. Article
  2. Article
  3. Recognition of a Novel Gene Signature for Human Glioblastoma.International journal of molecular sciences · 2022
    Article
  4. Article
  5. Article
  6. Article
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 5 institutions in 1 country.

Chengli Miao1] Retroperitoneal Tumors Center, Peking University International Hospital, Beijing, P.R. China [2] Department of Surgical Oncology, Beijing Shijitan Hospital, Capital Medical University (The 9th affiliated hospital of Peking University), Beijing, P.R. China.
Ding LiuDepartment of Neurology, The Third Hospital of Xiangya, Central South University, Changsha, Hunan, P.R. China.
Feng Zhang1] National Engineering Laboratory for Druggable Gene and Protein Screening, Northeast Normal University, Changchun 130024, Jilin Province, P.R. China [2] Chinese Academy of Sciences Key Laboratory of Genome Sciences and Information, Beijing Institute of Genomics, Chinese Academy of Sciences, Beijing, P.R. China.
Youxin WangBeijing Municipal Key Laboratory of Clinical Epidemiology, School of Public Health, Capital Medical University, Beijing 100069, China.
Yanbin ZhangDepartment of Surgical Oncology, Beijing Shijitan Hospital, Capital Medical University (The 9th affiliated hospital of Peking University), Beijing, P.R. China.
Junhui YuDepartment of Surgical Oncology, Beijing Shijitan Hospital, Capital Medical University (The 9th affiliated hospital of Peking University), Beijing, P.R. China.
Zhanzhi ZhangDepartment of Surgical Oncology, Beijing Shijitan Hospital, Capital Medical University (The 9th affiliated hospital of Peking University), Beijing, P.R. China.
Gang LiuDepartment of Surgical Oncology, Beijing Shijitan Hospital, Capital Medical University (The 9th affiliated hospital of Peking University), Beijing, P.R. China.
Bing LiDepartment of Surgical Oncology, Beijing Shijitan Hospital, Capital Medical University (The 9th affiliated hospital of Peking University), Beijing, P.R. China.
Xing LiuDepartment of Surgical Oncology, Beijing Shijitan Hospital, Capital Medical University (The 9th affiliated hospital of Peking University), Beijing, P.R. China.
Chenghua LuoRetroperitoneal Tumors Center, Peking University International Hospital, Beijing, P.R. China.
Capital Medical University · CNBeijing Shijitan Hospital · CNPeking University · CNCentral South University · CNNortheast Normal University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Primary retroperitoneal liposarcoma is generally regarded as a genetic disorder. We have retrospectively genotyped 8 single nucleotide polymorphisms (SNPs) in 6 candidate genes (MDM2, CDK4, CDC27, FPGS, IGFN1, and PRAMEF13) in 138 patients and 131 healthy control subjects to evaluate the effects of genetic factors on individual susceptibility to primary retroperitoneal liposarcoma in Chinese population. Three SNPs (rs2870820, rs1695147, rs3730536) of MDM2 showed significant differences in single-loci genotypes and allele frequencies between case and control groups (p < 0.05). The minor allele G of SNP rs10760502 in FPGS (folylpolyglutamate synthase) gene was significantly associated with increased risk for primary retroperitoneal liposarcoma, compared with major allele A. Our data suggest that FPGS variant in Chinese population may affect individual susceptibility to primary retroperitoneal liposarcoma.

Indexed as

Genetic Predisposition to DiseasePolymorphism, Single NucleotideAdultAgedAllelesAmino Acid SequenceCase-Control StudiesComputational BiologyDNA Mutational AnalysisFemaleGene FrequencyGenetic Association StudiesGenotypeHumansLinkage DisequilibriumLiposarcomafolylpolyglutamate synthetasePeptide Synthases

Identifiers

PMID25765001
PMCPMC5390907
OpenAlexW2080687273

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.